Lineage plasticity, a process whereby cells change their phenotype to take on a different
molecular and/or histologic identity, is a key driver of cancer progression and therapy …

Drug resistance in cancer is often linked to changes in tumor cell state or lineage, but the
molecular mechanisms driving this plasticity remain unclear. Using murine organoid and …

The adrenal glands are paired endocrine organs that produce steroid hormones and
catecholamines required for life. Adrenocortical carcinoma (ACC) is a rare and often fatal …

Emerging evidence indicates that various cancers can gain resistance to targeted therapies
by acquiring lineage plasticity. Although various genomic and transcriptomic aberrations …

Abstract Treatment with androgen receptor pathway inhibitors (ARPIs) in prostate cancer
leads to the emergence of resistant tumors characterized by lineage plasticity and …

Lineage plasticity causes therapeutic resistance; however, it remains unclear how the fate
conversion and phenotype switching of cancer-associated fibroblasts (CAFs) are implicated …

Abstract Enhancer of Zeste Homolog 2 (EZH2) and androgen receptor (AR) are crucial
chromatin/gene regulators involved in the development and/or progression of prostate …

Cancer arises following alterations at different cellular levels, including genetic and
epigenetic modifications, transcription and translation dysregulation, as well as metabolic …

Prostate cancer has a long disease history and a wide variety and uncertainty in individual
patients' clinical progress. In recent years, we have seen a revolutionary advance in both …

Androgen receptor (AR) drives prostate cancer (PCa) development and progression. AR
chromatin binding profiles are highly plastic and form recurrent programmatic changes that …